WHO - Sanofi, a Partnership to Save Lives
November 21, 2012
Initiated in 2001 with a program to prevent sleeping sickness, Sanofi and WHO renewed their partnership in 2006 and extended it to cover leishmaniasis, Buruli ulcer, yaws and Chagas disease. Through this alliance, the number of people treated for sleeping sickness has been permanently reduced to fewer than 10,000 new cases a year(1). Since 2001, more than 170,000 patients have received treatment for what is a fatal disease if left untreated. This could lead to the sleeping sickness being eliminated by 2020.
Healthcare actions that WHO has been able to undertake or extend due to Sanofi’s support are given in the 2006-2011 Report:
In March 2011, Christopher A. Viehbacher, CEO of Sanofi, and Margaret Chan, Director-General of WHO, renewed their joint commitment to neglected tropical diseases for a further five years. This partnership was enabled by the willingness of both parties to provide access to healthcare and medicines for the world’s most disadvantaged communities. For Sanofi, this commitment for the 2001 to 2016 period will involve financial support worth $75M, together with donations of medicines.